Delivering strong performance in 2023

The Octapharma Group once again delivered impressive growth in 2023, with sales up 14.4% over the prior year to a new record of €3.266 billion. This growth was driven by a substantial increase in plasma collection and continuing strong demand for our products. Operating income was €436 million.

The cost of sales increased by 21.4% to €2.332 billion, reflecting substantially higher production and material costs. As a result, while gross profit for the year was €934 million, marginally higher than in 2022, gross margins declined to 28.6% from 32.7%.

Operating expenses for the year increased to €497 million from €412 million in 2022. Income before tax was €429 million compared with a record €503 million in 2022, while net income was €354 million. Net cash from operating activities was €260 million.

While some of the increase in costs is due to higher inflation, much of it is the result of increased investment in research and development, expanding into new markets and implementing our ambitious strategy to increase production by up to 50% by 2028, which is expected to drive future growth and profitability to new heights.

These results were robustly ahead of plan for 2023 and leave Octapharma well positioned to execute our strategy for long-term, sustainable growth. We are well capitalised, and will continue to invest in increasing plasma collection, streamlining and developing our operations, and growing production, and in our strategy to attract and retain talent by ensuring Octapharma remains an employer of choice in our industry.

The benefits of these investments are already being reflected in our operations and that, combined with robust inventories of raw plasma, give us confidence that we will deliver another strong set of results in 2024.

This success would not have been possible without the commitment and support of Octapharma employees around the world. Together, we are on track to continue growing our company and helping even more patients in need around the world.

Roger Mächler
Chief Financial Officer

“We are well capitalised, and will continue to invest in increasing plasma collection, streamlining and developing our operations, and growing production, and in our strategy to attract and retain talent by ensuring Octapharma remains an employer of choice in our industry.”